Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Commitments and Contingencies [Line Items] | ||
| Terms agreement description | Under the August 2023 work orders, Minaris converted the Company’s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company’s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company’s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to Minaris to extend the initial term of the Minaris Agreement by 18 months through August 2026. | |
| Research and development expense | $ 142,674 | $ 97,203 |
| Rese-Cel and MuSK-CAART [Member] | ||
| Commitments and Contingencies [Line Items] | ||
| Early termination fee | $ 1,080 | |
| Wuxi Agreement | ||
| Commitments and Contingencies [Line Items] | ||
| Lease expiration month | 18 months | |
| Early termination fee | $ 1,500 | |
| Lonza Agreement | ||
| Commitments and Contingencies [Line Items] | ||
| Lease expiration month | 18 months | |
| Payment term | 12 months | |
| X | ||||||||||
- Definition Commitments and contingencies disclosure. No definition available.
|
| X | ||||||||||
- Definition Initial Terms of Agreement, Description No definition available.
|
| X | ||||||||||
- Definition Lease Expiration Month No definition available.
|
| X | ||||||||||
- Definition Payment of obligation, term. No definition available.
|
| X | ||||||||||
- Definition The amount of early contract termination fees included in liabilities subject to compromise. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|